Oscar van Loosbroek, Author at Treeway

Top-line results from Phase III ADORE study in ALS

Jan 18, 2024

In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122...

Treeway announces first patient enrolled in the Phase 2a ASURE clinical trial exploring the safety and effectiveness of oral edaravone to delay disease progression in Alzheimer’s patients

Mar 6, 2023

Tilburg, March 6, 2023 – Treeway, in collaboration with the Alzheimer Drug Discovery Foundation (ADDF), announces today the successful enrollment of the first patient in the Alzheimer’s Disease Study Using Oral Edaravone (ASURE), Phase 2a clinical trial. The trial...